Methocarbamol - Generic Drug Details

What are the generic drug sources for methocarbamol and what is the scope of freedom to operate?

Methocarbamol is the generic ingredient in five branded drugs marketed by Dr Reddys, Marsam Pharms Llc, Am Regent, Baxter Hlthcare Corp, Eugia Pharma, Fresenius Kabi Usa, Gland Pharma Ltd, Monterey Pharms Llc, Navinta Llc, Norvium Bioscience, Sagent Pharms Inc, Slate Run Pharma, Somerset Theraps Llc, Hikma, Ferndale Labs, Forest Labs, Able, Allied, Am Therap, Ani Pharms, Ascot, Aurobindo Pharma Ltd, Beximco Pharms Usa, Chartwell Molecular, Clonmel Hlthcare, Fosun Pharma, Granules, Hangzhou Binjiang, Heather, Hetero Labs Ltd Iii, Hikma Intl Pharms, Hlthcare, Impax Labs, Inwood Labs, Ivax Sub Teva Pharms, Kv Pharm, Mikart, Mylan, Nylos, Oxford Pharms, Pioneer Pharms, Prinston Inc, Puracap Pharm, Purepac Pharm, Roxane, Sandoz, Solvay, Sun Pharm Industries, Superpharm, Tablicaps, Upsher Smith, Watson Labs, and Endo Operations, and is included in seventy-four NDAs. Additional information is available in the individual branded drug profile pages.

There are twenty-seven drug master file entries for methocarbamol. Sixty-two suppliers are listed for this compound.

Summary for methocarbamol

US Patents:	0
Tradenames:	5
Applicants:	53
NDAs:	74
Drug Master File Entries:	27
Finished Product Suppliers / Packagers:	62
Raw Ingredient (Bulk) Api Vendors:	105
Clinical Trials:	10
Patent Applications:	5,418
Drug Prices:	Drug price trends for methocarbamol
Drug Sales Revenues:	Drug sales revenues for methocarbamol
What excipients (inactive ingredients) are in methocarbamol?	methocarbamol excipients list
DailyMed Link:	methocarbamol at DailyMed

See drug prices for methocarbamol

See drug sales revenues for methocarbamol

Recent Clinical Trials for methocarbamol

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Arthritis Innovation Corporation	Phase 3
Allucent	Phase 3
Prisma Health-Upstate	Phase 4

See all methocarbamol clinical trials

Pharmacology for methocarbamol

Drug Class	Muscle Relaxant
Physiological Effect	Centrally-mediated Muscle Relaxation

Medical Subject Heading (MeSH) Categories for methocarbamol

Muscle Relaxants, Central

Anatomical Therapeutic Chemical (ATC) Classes for methocarbamol

M03BA	Carbamic acid esters
M03B	MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS
M03	MUSCLE RELAXANTS
M	Musculo-skeletal system

US Patents and Regulatory Information for methocarbamol

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Ferndale Labs	DELAXIN	methocarbamol	TABLET;ORAL	085454-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Roxane	METHOCARBAMOL	methocarbamol	TABLET;ORAL	088646-001	Feb 29, 1984		DISCN	No	No
Prinston Inc	METHOCARBAMOL	methocarbamol	TABLET;ORAL	086988-002	Approved Prior to Jan 1, 1982	AA	RX	No	No
Purepac Pharm	METHOCARBAMOL	methocarbamol	TABLET;ORAL	085718-001	Approved Prior to Jan 1, 1982		DISCN	No	No

Methocarbamol Market Analysis and Financial Projection Experimental

Methocarbamol Tablets Market: Dynamics and Financial Trajectory

Introduction to Methocarbamol

Methocarbamol, a muscle relaxant discovered in the early 1950s and approved in 1957, has become a crucial component in the management of musculoskeletal conditions. It is widely recognized for its effectiveness in treating muscle spasms, stiffness, and pain associated with injuries or chronic disorders[1][5].

Market Growth Drivers

Increasing Demand for Non-Opioid Pain Management

The ongoing opioid crisis has led healthcare providers to seek safer alternatives for pain management. Methocarbamol, being non-addictive, is increasingly favored, boosting its demand across various markets. This shift towards non-opioid solutions is a significant driver of the methocarbamol tablets market[1].

Aging Population and Chronic Conditions

Musculoskeletal disorders, such as back pain, arthritis, and muscle strain, are becoming more common due to sedentary lifestyles and an aging population. The World Health Organization (WHO) reports that one in four adults will experience a musculoskeletal condition during their lifetime, underscoring the growing demand for effective treatments like methocarbamol tablets[1].

Innovations in Drug Formulations

Companies are investing in innovative formulations, such as extended-release tablets and combination therapies with anti-inflammatory agents. These multi-action therapies offer enhanced effectiveness, catering to a broader range of patients and driving market growth[1].

Expanding Healthcare Access

Developing nations are witnessing a surge in healthcare spending and improved access to medical resources. This has led to increased adoption of methocarbamol tablets in regions where awareness and treatment of musculoskeletal conditions were previously limited[1].

Market Size and Growth Projections

The muscle relaxant drugs market, which includes methocarbamol, is expected to grow significantly. The global muscle relaxant drugs market size is projected to increase from $4.46 billion in 2023 to $6.55 billion by 2028, with a compound annual growth rate (CAGR) of 7.9%[3].

Regional Market Analysis

North America was the largest region in the muscle relaxant drugs market in 2023, followed by other regions such as Asia-Pacific, Western Europe, and Eastern Europe. The global methocarbamol tablet market is segmented into regions including North America, Europe, Asia Pacific, Middle East & Africa, and Latin America[3][4].

Financial Trajectory

Revenue Growth

The methocarbamol tablets market is experiencing robust revenue growth. The market size is expected to see steady growth over the next decade, making it a lucrative area for investment. Analysts forecast that the methocarbamol market will witness significant annual growth, driven by increasing demand for non-opioid pain management solutions and innovations in drug formulations[1][4].

Strategic Acquisitions and Partnerships

Recent strategic acquisitions, such as Corona Remedies' acquisition of the muscle relaxant brand Myoril from Sanofi India, highlight the market's growth potential. Such moves fortify companies' positions in the burgeoning muscle relaxant market and indicate a trend of consolidation and expansion[3].

Investment in Digital Platforms

The global rise of e-commerce and online pharmacies has significantly increased the accessibility of methocarbamol tablets. Investors focusing on digital platforms can tap into a rapidly growing consumer base, further driving market growth[1].

Market Segmentation

By Drug Type

The muscle relaxant drugs market, including methocarbamol, is segmented by drug type into skeletal muscle relaxants, facial muscle relaxants, and neuromuscular blocking agents. Methocarbamol falls under the category of skeletal muscle relaxants[3].

By Formulation

Methocarbamol tablets are available in various formulations, including standard and extended-release forms. The market is also seeing the development of combination therapies and patient-centric products such as chewable tablets and liquid formulations[1][4].

By Route of Administration

The primary route of administration for methocarbamol is oral, although other forms like injectable and topical formulations are also available[3].

Challenges and Opportunities

Regulatory Complexities

Despite its promising growth, the methocarbamol tablets market faces challenges such as regulatory complexities and limited awareness in certain regions. Addressing these obstacles through education, advocacy, and transparent communication is essential for sustained market expansion[1].

Innovation and Accessibility

Companies are investing in user-friendly formats and digital platforms to enhance accessibility. Innovations in drug formulations and the integration of muscle relaxants into pain management protocols offer significant opportunities for growth[1][3].

Key Players and Market Strategies

Key companies such as Endo Pharmaceuticals and Virtus Pharmaceuticals are focusing on building their product portfolios and expanding their business through strategic partnerships and acquisitions. These companies are also investing in research and development to capitalize on the expanding segment of muscle relaxant drugs[4].

Consumer Behavior and Market Trends

The market is witnessing a trend towards personalized medicine and research in alternative therapies. The integration of muscle relaxants into pain management protocols and the advent of botulinum toxin injections are also significant trends. Consumer behavior is shifting towards safer, non-addictive pain management solutions, further driving the demand for methocarbamol tablets[3].

Technological and R&D Trends

Recent innovations include the development of combination therapies and extended-release formulations. Companies are also focusing on improving the side effect profiles of muscle relaxant drugs. The use of biotechnologies and synthesis technologies to enhance drug efficacy is another area of focus[1][2].

Conclusion

The methocarbamol tablets market is poised for unprecedented growth driven by increasing demand for non-opioid pain management solutions, innovations in drug formulations, and expanding healthcare access. Despite facing regulatory and awareness challenges, the market's potential is significant, making it a lucrative area for investment and strategic growth.

Key Takeaways

• Growing Demand: Increasing demand for non-opioid pain management solutions drives the methocarbamol tablets market.
• Innovations: Extended-release formulations and combination therapies enhance market growth.
• Expanding Access: Improved healthcare spending and digital platforms increase accessibility.
• Regulatory Challenges: Addressing regulatory complexities and limited awareness is crucial.
• Market Segmentation: The market is segmented by drug type, formulation, and route of administration.
• Key Players: Companies like Endo Pharmaceuticals and Virtus Pharmaceuticals are key players.
• Consumer Trends: Shift towards personalized medicine and safer pain management solutions.

FAQs

What is methocarbamol used for?

Methocarbamol is used to treat muscle spasms, stiffness, and pain associated with musculoskeletal conditions, injuries, or chronic disorders.

Why is methocarbamol preferred over opioids?

Methocarbamol is preferred because it does not have addictive properties, making it a safer choice for managing musculoskeletal pain without the risk of dependency.

What are the key drivers of the methocarbamol tablets market?

Key drivers include increasing demand for non-opioid pain management solutions, innovations in drug formulations, and expanding healthcare access.

Which regions are leading the methocarbamol tablets market?

North America is the largest region in the muscle relaxant drugs market, followed by Asia-Pacific, Western Europe, and Eastern Europe.

What are the challenges faced by the methocarbamol tablets market?

The market faces challenges such as regulatory complexities and limited awareness in certain regions, which need to be addressed through education and advocacy.

Cited Sources

1. Market Research Intellect: Global Demand Surge: Methocarbamol Tablets Market Sees Robust Growth.
2. Daiichi Sankyo Group Value Report 2018: Daiichi Sankyo Group Value Report 2018.
3. The Business Research Company: Muscle Relaxant Drugs Global Market Report 2024.
4. Cognitive Market Research: Methocarbamol Tablet Market Report 2024 (Global Edition).
5. StatPearls - NCBI: Methocarbamol.